Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 1,797 |
|
|||||
| News | (1) | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aldeyra Therapeutics Inc | ALDX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.16 | 4.06% | 4.10 | 08:00:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.94 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 11 | 1,797 | - | 1.42 - 11.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:13:04 | 1 | $ 4.0554 | USD |
Aldeyra Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 232.05M | 58.90M | - | 0 | -37.54M | -0.64 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aldeyra Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALDX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.97 | 4.18 | 3.79 | 3.92 | 451,440 | 0.13 | 3.27% |
| 1 Month | 3.12 | 4.97 | 3.12 | 4.18 | 862,100 | 0.98 | 31.41% |
| 3 Months | 3.15 | 4.97 | 2.71 | 3.77 | 585,499 | 0.95 | 30.16% |
| 6 Months | 1.57 | 4.97 | 1.46 | 2.90 | 1,550,496 | 2.53 | 161.15% |
| 1 Year | 9.48 | 11.97 | 1.42 | 4.53 | 1,356,363 | -5.38 | -56.75% |
| 3 Years | 10.61 | 15.95 | 1.42 | 6.73 | 1,095,391 | -6.51 | -61.36% |
| 5 Years | 8.08 | 15.95 | 1.42 | 6.89 | 888,475 | -3.98 | -49.26% |
Aldeyra Therapeutics Description
| Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. |
